Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Prostate cancer (PCa) is the second most common cause of cancer‐related mortality in men
in the United States. The androgen receptor (AR) and the physiological pathways it …

In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17, 20-lyase
(CYP17), the key enzyme which catalyzes the biosynthesis of androgens from progestins, 3β …

Galeterone (Gal) is a first-in-class multi-target oral small molecule that will soon enter pivotal
phase III clinical trials in castration resistant prostate cancer (CRPC) patients. Gal disrupts …

Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the
androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an …

Simple Summary Prostate cancer progression is mainly driven by the androgen receptor
(AR) signaling pathway and its inhibition has been the cornerstone in the treatment of …

Major advances have been achieved recently in the treatment of metastatic castration-
resistant prostate cancer, resulting in significant improvements in quality of life and survival …

Motivation Successful development and application of precision oncology approaches
require robust elucidation of the genomic landscape of a patient's cancer and, ideally, the …

Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in the
United States and its progression is tightly associated with the androgen/androgen receptor …

Introduction: Prostate cancer is the most common cancer in elderly males. Regardless of the
initial hormonal treatment in metastatic disease, a significant proportion of patients develop …